Nivolumab

CheckMate 649

Nivolumab CheckMate 649

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

OS

ADJUSTMENTS

Quality of life

Serious and disabling adverse effects

Other adjustments

Nivolumab CheckMate 649

FINAL SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

4

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers
Therapeutic Indication: First-line treatment for patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a CPS ≥5
Experimental Arm: Nivolumab + Fluoropyrimidine and platinum ChT (FOLFOX or CAPOX)
Control Arm: ChT (FOLFOX or CAPOX)